Treatment of the elderly with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors: Focus on drug interactions

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 6, Issue 3, 2001, Pages 219-229

  Davidson, Michael H ^a  

^a RADIANT RESEARCH   (United States)

Author keywords

Cardiovascular disease; Coronary heart disease; Drug interactions; Statins

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; SIMVASTATIN;

AGE; AGED; AGING; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; ENZYME INHIBITION; HIGH RISK POPULATION; HUMAN; HYPERTENSION; MYOPATHY; OBESITY; POLYPHARMACY; PRIORITY JOURNAL; SECONDARY PREVENTION; STROKE;

EID: 0035730558     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/107424840100600302     Document Type: Article

References (68)

1. Cardiovascular risk factors in the elderly
2. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II)
3. Time trends in the use of cholesterol-lowering agents in older adults: The Cardiovascular Health Study
4. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
5. Prediction of coronary heart disease using risk factor categories
6. Cholesterollowering therapy in women and elderly patients with myocardial infarction or angina pectoris: Findings from the Scandinavian Simvastatin Survival Study (4S)
7. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators
8. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the cholesterol and recurrent events (CARE) trial
9. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
10. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
11. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas coronary atherosclerosis prevention study
12. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial
13. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials
14. Reductase inhibitor monotherapy and stroke prevention
15. Management of dyslipidemia in adults with diabetes
16. Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease
17. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin
18. Elderly patients with hypercholesterolaemia: A double-blind study of the efficacy, safety, and tolerability of fluvastatin
19. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: Early safety and efficacy experience
20. The design of a prospective study of pravastatin in the elderly at risk (PROSPER)
21. Effect of atorvastatin compared with placebo on cerebrovascular endpoints in patients with a previous stroke or TIA - The SPARCL study
22. Effect of lowering LDL-C beyond currently recommended minimum targets - The Treating to New Targets (TNT) study
23. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease
24. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: Forecasting the incremental benefits of preventing coronary and cerebrovascular events
25. Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients
26. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations
27. Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors
28. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid
29. Epidemiology of adverse drug reactions in the elderly by drug class
30. Influence of liver function on drug disposition
31. Update: Clinically significant cytochrome P-450 drug interactions
32. Recent advances: The cytochrome P450 enzymes
33. Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions
34. Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved
35. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: Effect on human cytochrome P- 450 and implications for metabolic drug interactions
36. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine
37. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients
38. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients
39. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin
40. Low-dose simvastatin for the treatment of hypercholesterolaemia in recipients of cardiac transplantation
41. Safety and efficacy of low dose simvastatin in cardiac transplant recipients treated with cyclosporine
42. Fluvastatin in combination with cyclosporin in renal transplant recipients: A review of clinical and safety experience
43. Does differing metabolism by cytochrome P450 have clinical importance?
44. Clinical pharmacokinetics of fibric acid derivatives (fibrates)
45. Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy
46. Rhabdomyolysis associated with simvastatin-gemfibrozil therapy
47. Rhabdomyolysis after taking atorvastatin with gemfibrozil
48. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia
49. Treatment of hyperlipidemia with combined niacin-statin regimens
50. Fluvastatin with and without niacin for hypercholesterolemia
51. Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia
52. Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin
53. The interaction of diltiazem with lovastatin and pravastatin
54. Atorvastatin pharmacokinetic interactions with other CYP3A4 substrates: Erythromycin and ethinyl estradiol
55. Potential interaction between warfarin and fluvastatin
56. Potential warfarin-fluvastatin interaction
57. Mibefradil - A new calcium-channel blocker
58. Rhabdomyolysis associated with lovastatin and erythromycin use
59. Differences in metabolism of lovastatin and pravastatin as assessed by CYP3A inhibition with erythromycin
60. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin
61. Simvastatin but not pravastatin is very susceptible to interaction with the CYP 3A4 inhibitor itraconazole
62. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole
63. Newer antidepressants and the cytochrome P450 system
64. Hyperlipidemia associated with HIV protease inhibitor use: Pathophysiology, prevalence, risk factors and treatment
65. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin